It has been estimated that cardiovascular disease (CVD) claims 18.6 million lives per year. As World Heart Day seeks to raise awareness on CVD prevention and management, what are some ways your patients can reduce their risk?
Echocardiographic phenotypes significantly improved the prognostic performance on top of the ARIC HF risk score, and discriminative values were “consistently observed on top of traditionally defined cardiac structure or function abnormalities.”
The risk for recurrent MACE was high among survivors of a first ever acute coronary syndrome with a substantial number of these being fatal; 34.4% had MACE within 1 year and 48.4% in 3 years.
This study evaluated the effects of hemodynamic-guided management of heart failure on composite mortality and heart failure events.
The authors describe how to diagnose and treat patients with heart failure who develop COVID-19 disease in this case study.
The phase 3 EMPEROR-Preserved trial assessed empagliflozin in 5988 adults with heart failure with preserved ejection fraction, with and without diabetes.
Researchers determined the effects of early rhythm control therapy in patients diagnosed with atrial fibrillation with signs and symptoms of heart failure.
46 percent of those diagnosed in acute care had potential heart failure symptoms in previous six months.
Despite an increasing emphasis on HFmrEF over the past several years, there is a lack of authoritative guidance surrounding therapeutic approaches for these patients.
Increase of 585 percent seen in methamphetamine-associated cardiomyopathy/heart failure hospitalizations from 2008 to 2018
